• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

进化视角、异质性与卵巢癌:从过去到现在的复杂故事。

Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.

机构信息

Department of Surgery, The Oncology Institute 'Prof. Dr. Ion Chiricuta', 34-36 Republicii street, 400015 , Cluj-Napoca, Romania.

Department of Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

出版信息

J Ovarian Res. 2022 Jun 3;15(1):67. doi: 10.1186/s13048-022-01004-1.

DOI:10.1186/s13048-022-01004-1
PMID:35659345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9164402/
Abstract

Ovarian cancer is composed of a complex system of cells best described by features such as clonal evolution, spatial and temporal genetic heterogeneity, and development of drug resistance, thus making it the most lethal gynecologic cancer. Seminal work on cancer as an evolutionary process has a long history; however, recent cost-effective large-scale molecular profiling has started to provide novel insights coupled with the development of mathematical algorithms. In the current review, we have systematically searched for articles that focused on the clonal evolution of ovarian cancer to offer the whole landscape of research that has been done and highlight future research avenues given its characteristic features and connections to evolutionary biology.

摘要

卵巢癌由一个复杂的细胞系统组成,其特征最好用克隆进化、时空遗传异质性和耐药性发展等来描述,因此它是最致命的妇科癌症。癌症作为一个进化过程的开创性工作历史悠久;然而,最近具有成本效益的大规模分子分析开始提供新的见解,并结合数学算法的发展。在本综述中,我们系统地搜索了专注于卵巢癌克隆进化的文章,提供了已经完成的研究全景,并鉴于其特征和与进化生物学的联系,强调了未来的研究方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5a2/9164402/9de2ead411f2/13048_2022_1004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5a2/9164402/9de2ead411f2/13048_2022_1004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5a2/9164402/9de2ead411f2/13048_2022_1004_Fig1_HTML.jpg

相似文献

1
Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.进化视角、异质性与卵巢癌:从过去到现在的复杂故事。
J Ovarian Res. 2022 Jun 3;15(1):67. doi: 10.1186/s13048-022-01004-1.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
4
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
6
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.聚(ADP-核糖)聚合酶(PARP)抑制剂治疗卵巢癌。
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
7
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血(尤其是癌症治疗所致贫血)的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
8
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
9
Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.在化疗期间及随访过程中,通过血清肿瘤标志物CA125对卵巢癌患者进行监测。
Dan Med J. 2018 Apr;65(4).
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

1
Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications.癌症的遗传图谱:机制、关键基因及治疗意义。
Clin Transl Oncol. 2025 Aug 17. doi: 10.1007/s12094-025-04019-4.
2
Detecting vascular normalization in epithelial ovarian cancer.检测上皮性卵巢癌中的血管正常化。
Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.
3
Claudin-4 remodeling of nucleus-cell cycle crosstalk maintains ovarian tumor genome stability and drives resistance to genomic instability-inducing agents.紧密连接蛋白4重塑核-细胞周期串扰维持卵巢肿瘤基因组稳定性并驱动对基因组不稳定诱导剂的抗性。

本文引用的文献

1
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.聚腺苷二磷酸核糖聚合酶抑制剂与免疫疗法在卵巢癌中的相互作用:一种新联合治疗方案背后的原理。
Int J Mol Sci. 2022 Mar 31;23(7):3871. doi: 10.3390/ijms23073871.
2
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.计算模型研究卵巢癌动力学变化,提出最佳治疗和筛查策略。
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25). doi: 10.1073/pnas.2026663118.
3
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
bioRxiv. 2024 Sep 7:2024.09.04.611120. doi: 10.1101/2024.09.04.611120.
4
New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.高级别浆液性卵巢癌患者治疗反应的新型免疫表型。
Front Immunol. 2024 Jun 14;15:1394497. doi: 10.3389/fimmu.2024.1394497. eCollection 2024.
5
Preclinical efficacy of CBR-5884 against epithelial ovarian cancer cells by targeting the serine synthesis pathway.CBR-5884通过靶向丝氨酸合成途径对上皮性卵巢癌细胞的临床前疗效。
Discov Oncol. 2024 May 11;15(1):154. doi: 10.1007/s12672-024-01013-0.
6
The Role of Glutathione Transferase Omega-Class Variant Alleles in Individual Susceptibility to Ovarian Cancer.谷胱甘肽转移酶 Omega 类变异等位基因在个体对卵巢癌易感性中的作用。
Int J Mol Sci. 2024 May 3;25(9):4986. doi: 10.3390/ijms25094986.
7
Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA.通过 ctDNA 的纵向分析探索卵巢癌患者的进化轨迹。
Clin Chem Lab Med. 2024 Apr 5;62(10):2070-2081. doi: 10.1515/cclm-2023-1266. Print 2024 Sep 25.
8
Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy.治疗性靶向核输出和进口受体在癌症及其在联合化疗中的潜力。
IUBMB Life. 2024 Jan;76(1):4-25. doi: 10.1002/iub.2773. Epub 2023 Aug 25.
9
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells.埃索美拉唑通过抑制卵巢癌细胞中的AKT/mTOR通路减轻顺铂耐药性。
Onco Targets Ther. 2023 Jun 20;16:425-440. doi: 10.2147/OTT.S406009. eCollection 2023.
10
Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins.通过血清代谢物和脂蛋白变化评估高级别浆液性卵巢癌的主要治疗效果
Metabolites. 2023 Mar 12;13(3):417. doi: 10.3390/metabo13030417.
PARP抑制剂与抗血管生成治疗联合用于晚期上皮性卵巢癌的理论依据:综述
Gynecol Oncol. 2021 Aug;162(2):482-495. doi: 10.1016/j.ygyno.2021.05.018. Epub 2021 Jun 3.
4
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.抗血管生成治疗与免疫检查点阻断联合作用可使血管免疫相互作用正常化,从而增强癌症免疫。
Exp Mol Med. 2020 Sep;52(9):1475-1485. doi: 10.1038/s12276-020-00500-y. Epub 2020 Sep 11.
5
Kinase Inhibitors and Ovarian Cancer.激酶抑制剂与卵巢癌
Cancers (Basel). 2019 Sep 12;11(9):1357. doi: 10.3390/cancers11091357.
6
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?卵巢癌的抗血管生成治疗:哪些患者最有可能从中获益?
Oncology (Williston Park). 2019 Jul 16;33(7):629378.
7
Application of Cell-free DNA Analysis to Cancer Treatment.游离DNA分析在癌症治疗中的应用。
N Engl J Med. 2018 Nov 1;379(18):1754-1765. doi: 10.1056/NEJMra1706174.
8
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.估算 2018 年全球癌症发病率和死亡率:GLOBOCAN 来源和方法。
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
9
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.奥拉帕利维持治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.
10
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.卵巢癌中恶性和免疫克隆动力学的界面。
Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.